Resolving sex and gender bias in COVID-19 vaccines R&D and beyond

Lavanya Vijayasingham, Shirin Heidari, Jean Munro, Saad Omer, Noni MacDonald

Producción científica: Contribución a una revistaComentario/debaterevisión exhaustiva

5 Citas (Scopus)

Resumen

The influence of sex and gender in immune response and vaccine outcomes is established in many disease areas, including in COVID-19. Yet, there are notable gaps in the consideration of sex and gender in the analysis and reporting of COVID-19 vaccines clinical trial data. The push for stronger sex and gender integration in vaccines science should be championed by all researchers and stakeholders across the R&D and access ecosystem–not just gender experts. This requires joint action on the tactical framing of customized value propositions (based on stakeholder motivations), the stronger enforcement of existing regulation, tools, and commitments, and aligning the overall agenda to parallel calls on intersectionality, equity diversity and inclusion.

Idioma originalEnglish
Número de artículo2035142
PublicaciónHuman Vaccines and Immunotherapeutics
Volumen18
N.º1
DOI
EstadoPublished - 2022

Nota bibliográfica

Funding Information:
This work is led by The Gender and Health Hub at UNU-IIGH, which receives grant funding from the Bill and Melinda Gates Foundation.

Publisher Copyright:
© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.

ASJC Scopus Subject Areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't

Huella

Profundice en los temas de investigación de 'Resolving sex and gender bias in COVID-19 vaccines R&D and beyond'. En conjunto forman una huella única.

Citar esto